{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:03:18Z","timestamp":1773093798253,"version":"3.50.1"},"reference-count":50,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to investigate the impact of 92 inflammatory proteins on the risk of cardiovascular disease (CVD) in patients with early rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included consecutive patients with early RA recruited between 1995 and 2002. Stored plasma samples were analyzed for 92 inflammatory proteins. CVD diagnoses were retrieved from national in-patient and cause-of-death registries. Statistical analyses were predesignated as hypothesis-driven or exploratory. For the latter, proteins were selected based on principal component analysis (ie, factor loading &gt; 0.5 within main components). Potential predictors of CVD and coronary artery disease (CAD) were assessed using Cox regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data on baseline levels of proteins and CVD were available for 163 patients. As hypothesized, levels of interleukin 17A (IL-17A) were associated with CVD (hazard ratio 1.35, 95% CI 1.02-1.78, adjusted for age, sex, hypertension, diabetes, smoking, and erythrocyte sedimentation rate [ESR]), although not significantly with CAD. Osteoprotegerin (OPG) levels were significantly associated with both outcomes, but only in crude models. No associations were observed for IL-6, tumor necrosis factor, monocyte chemotactic protein-1, or IL-8. In the exploratory analyses, MCP-3 in particular had significant associations with both outcomes in crude models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Circulating IL-17A at RA diagnosis predicted future CVD, although we cannot exclude the possibility that this finding is due to multiple testing. The association was independent of traditional CVD risk factors, and of ESR at the time of diagnosis. Further, OPG may be a predictor of CVD. We also identified some novel potential biomarkers for CVD in RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1078","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:57:26Z","timestamp":1714575446000},"page":"752-758","source":"Crossref","is-referenced-by-count":5,"title":["Circulating Interleukin 17A and Other Inflammatory Proteins May Predict Cardiovascular Disease in Early Rheumatoid Arthritis"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-7648","authenticated-orcid":false,"given":"Emil","family":"Rydell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-148X","authenticated-orcid":false,"given":"Lennart T.H.","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-2290","authenticated-orcid":false,"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"2024080105251898000_51.8.752.1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/rheumatology\/keaa374","article-title":"Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population","volume":"60","author":"L\u00f8gstrup","year":"2021","journal-title":"Rheumatology"},{"key":"2024080105251898000_51.8.752.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-211066"},{"key":"2024080105251898000_51.8.752.3","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2024080105251898000_51.8.752.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201334"},{"key":"2024080105251898000_51.8.752.5","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"2024080105251898000_51.8.752.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu459"},{"key":"2024080105251898000_51.8.752.7","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-11-0921"},{"key":"2024080105251898000_51.8.752.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204715"},{"key":"2024080105251898000_51.8.752.9","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/art.39267","article-title":"Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study","volume":"67","author":"Mantel","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024080105251898000_51.8.752.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61717-7"},{"key":"2024080105251898000_51.8.752.11","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"2024080105251898000_51.8.752.12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010922"},{"key":"2024080105251898000_51.8.752.13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10067-017-3657-y","article-title":"The effect of TNF-a antagonists on aortic stiffness and wave reflections: a meta-analysis","volume":"37","author":"Vlachopoulos","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2024080105251898000_51.8.752.14","first-page":"e26430","article-title":"Tumor necrosis factor-alpha inhibitors and cardiovascular risk in rheumatoid arthritis: a systematic review","volume":"14","author":"Nair","year":"2022","journal-title":"Cureus"},{"key":"2024080105251898000_51.8.752.15","doi-asserted-by":"publisher","DOI":"10.1186\/ar1717"},{"key":"2024080105251898000_51.8.752.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.25009"},{"key":"2024080105251898000_51.8.752.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht367"},{"key":"2024080105251898000_51.8.752.18","doi-asserted-by":"crossref","first-page":"828933","DOI":"10.3389\/fphar.2022.828933","article-title":"A role of IL-17 in rheumatoid arthritis patients complicated with atherosclerosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024080105251898000_51.8.752.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901126"},{"key":"2024080105251898000_51.8.752.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-010-0135-y"},{"key":"2024080105251898000_51.8.752.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.01.009"},{"key":"2024080105251898000_51.8.752.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148031"},{"key":"2024080105251898000_51.8.752.23","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3389\/fimmu.2020.01998","article-title":"Synergistic interaction between high bioactive IL-17A and joint destruction for the occurrence of cardiovascular events in rheumatoid arthritis","volume":"11","author":"Robert","year":"2020","journal-title":"Front Immunol"},{"key":"2024080105251898000_51.8.752.24","first-page":"69","article-title":"Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis","volume":"7","author":"Benucci","year":"2013","journal-title":"Biologics"},{"key":"2024080105251898000_51.8.752.25","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X12438080"},{"key":"2024080105251898000_51.8.752.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.216846"},{"key":"2024080105251898000_51.8.752.27","doi-asserted-by":"publisher","DOI":"10.1161\/hq1201.100229"},{"key":"2024080105251898000_51.8.752.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131037"},{"key":"2024080105251898000_51.8.752.29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.55563\/clinexprheumatol\/5p7mb4","article-title":"Osteoprotegerin and osteocalcin are associated with atherosclerosis in patients with rheumatoid arthritis: a prospective cohort study","volume":"39","author":"Wahlin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2024080105251898000_51.8.752.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.04.049"},{"key":"2024080105251898000_51.8.752.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140690"},{"key":"2024080105251898000_51.8.752.32","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000031524.49139.29"},{"key":"2024080105251898000_51.8.752.33","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127957.43874.BB"},{"key":"2024080105251898000_51.8.752.34","doi-asserted-by":"publisher","DOI":"10.1186\/ar3116"},{"key":"2024080105251898000_51.8.752.35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/acr.23318","article-title":"Course of grip force impairment in patients with early rheumatoid arthritis over the first five years after diagnosis","volume":"70","author":"Rydholm","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2024080105251898000_51.8.752.36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13075-020-02413-7","article-title":"Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study","volume":"23","author":"Rydell","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2024080105251898000_51.8.752.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2024080105251898000_51.8.752.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123919"},{"key":"2024080105251898000_51.8.752.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036715"},{"key":"2024080105251898000_51.8.752.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.07.023"},{"key":"2024080105251898000_51.8.752.41","doi-asserted-by":"crossref","first-page":"672255","DOI":"10.3389\/fimmu.2021.672255","article-title":"Validation of GWAS-identified variants for anti-TNF drug response in rheumatoid arthritis: a meta-analysis of two large cohorts","volume":"12","author":"S\u00e1nchez-Maldonado","year":"2021","journal-title":"Front Immunol"},{"key":"2024080105251898000_51.8.752.42","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/rheumatology\/keac581","article-title":"Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study","volume":"62","author":"Wadstr\u00f6m","year":"2023","journal-title":"Rheumatology"},{"key":"2024080105251898000_51.8.752.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200468"},{"key":"2024080105251898000_51.8.752.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3480-9"},{"key":"2024080105251898000_51.8.752.45","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024080105251898000_51.8.752.46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214943"},{"key":"2024080105251898000_51.8.752.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.042"},{"key":"2024080105251898000_51.8.752.48","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/life11090919","article-title":"Impact of interleukin-17 inhibitor therapy on arterial intima-media thickness among severe psoriatic patients","volume":"11","author":"Piros","year":"2021","journal-title":"Life"},{"key":"2024080105251898000_51.8.752.49","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2024080105251898000_51.8.752.50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12933-022-01626-1","article-title":"CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease","volume":"21","author":"Chang","year":"2022","journal-title":"Cardiovasc Diabetol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:35:57Z","timestamp":1722515757000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.3899\/jrheum.2023-1078"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1078","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}